the actual pharmacokinetic case for twice-weekly splitting, and what it doesn’t prove
Splitting a weekly dose into two smaller injections comes up constantly so here's the actual PK argument, separated from the outcome-data question, which is a different thing entirely.
Both semaglutide and tirzepatide have long half-lives (roughly a week), so a single weekly injection already produces fairly smooth drug levels — but there's still a peak-and-trough pattern around each shot. Splitting the same weekly total into two smaller injections spread out can, in theory, flatten that peak-trough swing further, which is the reasoning people give for fewer side-effect spikes.
What this does NOT prove: that splitting changes efficacy, total weight loss, or anything measured in an actual trial. Every phase 2/3 trial in this space dosed once weekly. The smoothing argument is real pharmacology. The "and therefore better outcomes" leap is not supported by anything published that I'm aware of.
best — the order this archive was captured in
this is exactly my position and I'm glad someone wrote the PK case out properly instead of me just saying "no data" for the hundredth time. the mechanism is plausible, the outcome claim is not evidenced.
right, and I think the community conflates "plausible mechanism" with "proven benefit" more than with most other dosing questions here
plausible mechanism gets people pretty far in this space generally, cagrilintide's whole story is plausible mechanism ahead of outcome data too
the peak-trough smoothing is real for basically any drug with this kind of terminal half-life, it's not specific pharmacology to these compounds, it's just what splitting any dose does to a concentration-time curve.
which is also why nobody's rushing to run a trial on it, the smoothing effect is well understood generically, the specific clinical question ("does it change GI tolerability enough to matter") is the actual open one
Good post, correctly separates the two claims. Flairing Explainer rather than Discussion because this is mostly settled pharmacology plus an honest "we don't know" on outcomes, not an open debate.
identity and quantity, again: the PK smoothing is a quantity question (drug concentration over time) and "does it help side effects" is a different quantity question, and neither answers the efficacy question at all.
worth saying the flip side too: splitting also means twice the injection sites, twice the vial punctures, and generally more room for dosing errors. the smoothing benefit has a hassle cost attached.
and twice the arithmetic, which is exactly where the mistakes happen in my experience reading this community's math errors
appreciate that this whole post is citation-honest, "no published outcome data" is a real and useful answer, better than pretending there's a trial that doesn't exist
SUSTAIN 6 and the STEP program are both once-weekly designs, pretty sure none of the major published trials tested a split schedule directly, so anyone hunting for a hidden RCT on this is going to come up empty.
would be a genuinely interesting small trial to actually run given how popular the practice is, surprised nobody's done it as a secondary endpoint somewhere
even if someone ran it, you'd want a fairly large n to detect a modest GI-tolerability difference, underpowered small trials on this exact question would probably just add noise to an already noisy topic